Ozlo, the developer behind noise-canceling Sleepbuds, is aggressively transitioning from a hardware-focused brand into a comprehensive sleep data platform. Revealed during CES in Las Vegas, the company is leveraging its proprietary sensor technology to forge partnerships with wellness giants, integrate AI-driven insights, and venture into the high-stakes medical device market.
Building a Data-Driven Sleep Ecosystem
Founded by former Bose engineers, Ozlo designed its iOS and Android SDK to ensure its first-party application serves as a blueprint for third-party integration. By utilizing sensors that track body movement and respiration rates, the company’s smart charging case processes data through machine learning to determine whether a user is relaxed or in a deep sleep state.
This capability is the foundation for a potential partnership with the meditation app Calm. While current data sharing between the two is limited, the vision is a “closed-loop” system: if a user’s respiration rate remains high during a breathing exercise, the app could automatically adjust content to be more effective. This provides content creators with tangible metrics on whether their wellness programs actually work in the real world.
AI Integration and Tinnitus Therapy
Ozlo is betting big on AI to deepen customer engagement. By November, the company launched “Sleep Patterns” to help users identify environmental factors disturbing their rest. A new AI-powered “sleep buddy” agent is scheduled for a Q2 release, designed to act as a conversational interface for users. Furthermore, the company is expanding into clinical territory with tinnitus therapy tools developed in collaboration with Walter Reed Hospital, which will launch as a premium subscription service later in 2026.
Hardware Evolution and EEG Capabilities
Beyond software, Ozlo is refining its physical product line. A next-generation case, arriving in Q2, will feature improved earbud seating, a dedicated Bluetooth pairing button, and a redesigned antenna for better connectivity. Simultaneously, the company is developing a bedside speaker to serve families and elderly users who may prefer not to use in-ear devices.
The most significant leap involves the recent acquisition of Segotia, an Irish neurotech firm. By integrating EEG-focused “hearable” technology, Ozlo intends to measure electrical brain signals directly from the ear. This move is expected to position the company as a key player in the medical device sector by 2027.
To support this rapid expansion, Ozlo is currently in the process of closing a Series B funding round. As the company scales, its ability to translate complex sleep data into actionable health outcomes will be the primary metric for its long-term market viability.
